msd

MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

pharmafile | October 8, 2018 | News story | Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis 

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department of Veteran Affairs.

The deal between the multibillion dollar pharma firm MSD, and the Samsung Biologics and Biogen Idec joint-venture Samsung Bioepis, will see MSD supply Renflexis, a biosimilar of Janssen’s Remicade (Infliximab) to the US federal agency that provides healthcare services to military veterans.

The deal comes after a 2013 deal between MSD and Samsung Bioepis settled that Merck would be responsible for commercialising multiple biosimilar candidates, in particular partnered territories.

Advertisement

Meanwhile Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and regulatory registration.

The biosimilar of the blockbuster monoclonal antibody which is used to treat autoimmune diseases such as Crohn’s disease, ulcerative colitis, psoriasis and rheumatoid arthritis gained FDA approval in April 2017.

Louis Goss

Related Content

Samsung Bioepis announces launch of two new denosumab biosimilars in Europe

Samsung Bioepis has announced the European launch of Obodence and Xbryk, two new denosumab biosimilars …

trial

Biogen and Stoke report positive results for Dravet syndrome drug

Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …

Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine

Johnson & Johnson company Janssen has announced that the results from its phase 2 trial …

The Gateway to Local Adoption Series

Latest content